Almenar-Pérez, E.; Sánchez-Fito, T.; Ovejero, T.; Nathanson, L.; Oltra, E.
Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. Pharmaceutics 2019, 11, 126.
https://doi.org/10.3390/pharmaceutics11030126
AMA Style
Almenar-Pérez E, Sánchez-Fito T, Ovejero T, Nathanson L, Oltra E.
Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. Pharmaceutics. 2019; 11(3):126.
https://doi.org/10.3390/pharmaceutics11030126
Chicago/Turabian Style
Almenar-Pérez, Eloy, Teresa Sánchez-Fito, Tamara Ovejero, Lubov Nathanson, and Elisa Oltra.
2019. "Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments" Pharmaceutics 11, no. 3: 126.
https://doi.org/10.3390/pharmaceutics11030126
APA Style
Almenar-Pérez, E., Sánchez-Fito, T., Ovejero, T., Nathanson, L., & Oltra, E.
(2019). Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments. Pharmaceutics, 11(3), 126.
https://doi.org/10.3390/pharmaceutics11030126